Premenstrual Syndrome – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Premenstrual Syndrome – Pipeline Review, H2 2019’, provides an overview of the Premenstrual Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Premenstrual Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premenstrual Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Premenstrual Syndrome

– The report reviews pipeline therapeutics for Premenstrual Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Premenstrual Syndrome therapeutics and enlists all their major and minor projects

– The report assesses Premenstrual Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Premenstrual Syndrome”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Premenstrual Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Premenstrual Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Asarina Pharma AB

MetVital Inc

Pherin Pharmaceuticals Inc

Transdermal Delivery Solutions Corp”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Premenstrual Syndrome - Overview

Premenstrual Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Premenstrual Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Premenstrual Syndrome - Companies Involved in Therapeutics Development

Asarina Pharma AB

Pherin Pharmaceuticals Inc

Premenstrual Syndrome - Drug Profiles

(estrogen + progesterone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PH-80PMD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sepranolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 to Antagonize GABAA Receptor for PMDD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 to Antagonize GABAA Receptor for PMDD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Premenstrual Syndrome - Dormant Projects

Premenstrual Syndrome - Product Development Milestones

Featured News & Press Releases

Aug 30, 2018: Asarina Pharma presents first-in-class PMDD treatment to investors in Gothenburg and Stockholm

Jul 09, 2018: Chief Medical Officer appointed for clinical trials of world’s first therapy targeting both PMDD and menstrual migraine

Apr 24, 2018: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD

Apr 24, 2018: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD

Apr 06, 2018: Asarina Pharma announces the start of a clinical Phase IIB study in patients with premenstrual dysphoric disorder

Apr 04, 2018: Asarina Pharma starts recruiting patients for Phase IIB clinical trial of Sepranolone, the world’s first treatment specifically targeting PMDD (premenstrual dysphoric disorder), the severest form of PMS

Apr 03, 2017: Asarina Pharma Phase IIa clinical study with Sepranolone in premenstrual dysphoric disorder meets primary endpoint.

Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD)

Jun 12, 2014: Umecrine Mood reports preliminary data from exploratory Phase II study in premenstrual dysphoric disorder

Dec 16, 2013: Patient recruitment completed in the Phase I/II study of Umecrine Mood’s candidate drug for severe premenstrual symptoms

May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Premenstrual Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Premenstrual Syndrome – Pipeline by Asarina Pharma AB, H2 2019

Premenstrual Syndrome – Pipeline by MetVital Inc, H2 2019

Premenstrual Syndrome – Pipeline by Pherin Pharmaceuticals Inc, H2 2019

Premenstrual Syndrome – Pipeline by Transdermal Delivery Solutions Corp, H2 2019

Premenstrual Syndrome – Dormant Projects, H2 2019”

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports